Chronic Condition Clusters and Polypharmacy among Adults.

International journal of family medicine Pub Date : 2012-01-01 Epub Date: 2012-08-01 DOI:10.1155/2012/193168
Ami Vyas, Xiaoyun Pan, Usha Sambamoorthi
{"title":"Chronic Condition Clusters and Polypharmacy among Adults.","authors":"Ami Vyas,&nbsp;Xiaoyun Pan,&nbsp;Usha Sambamoorthi","doi":"10.1155/2012/193168","DOIUrl":null,"url":null,"abstract":"<p><p>Objective. The primary objective of the study was to estimate the rates of polypharmacy among individuals with multimorbidity defined as chronic condition clusters and examine their associations with polypharmacy. Methods. Cross-sectional analysis of 10,528 individuals of age above 21, with at least one physical condition in cardiometabolic (diabetes or heart disease or hypertension), musculoskeletal (arthritis or osteoporosis), and respiratory (chronic obstructive pulmonary disease (COPD) or asthma) clusters from the 2009 Medical Expenditure Panel Survey. Chi-square tests and logistic regressions were performed to analyze the association between polypharmacy and multimorbidity. Results. Polypharmacy rates varied from a low of 7.2% among those with respiratory cluster to a high of 64.1% among those with all three disease clusters. Among those with two or more disease clusters, the rates varied from 28.3% for musculoskeletal and respiratory clusters to 41.8% for those with cardiometabolic and respiratory clusters. Individual with cardiometabolic conditions alone or in combination with other disease clusters were more likely to have polypharmacy. Compared to those with musculoskeletal and respiratory conditions, those with cardiometabolic and respiratory conditions had 1.68 times higher likelihood of polypharmacy. Conclusions. Rates of polypharmacy differed by specific disease clusters. Individuals with cardiometabolic condition were particularly at high risk of polypharmacy, suggesting greater surveillance for adverse drug interaction in this group.</p>","PeriodicalId":89569,"journal":{"name":"International journal of family medicine","volume":"2012 ","pages":"193168"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/193168","citationCount":"68","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of family medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2012/193168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/8/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 68

Abstract

Objective. The primary objective of the study was to estimate the rates of polypharmacy among individuals with multimorbidity defined as chronic condition clusters and examine their associations with polypharmacy. Methods. Cross-sectional analysis of 10,528 individuals of age above 21, with at least one physical condition in cardiometabolic (diabetes or heart disease or hypertension), musculoskeletal (arthritis or osteoporosis), and respiratory (chronic obstructive pulmonary disease (COPD) or asthma) clusters from the 2009 Medical Expenditure Panel Survey. Chi-square tests and logistic regressions were performed to analyze the association between polypharmacy and multimorbidity. Results. Polypharmacy rates varied from a low of 7.2% among those with respiratory cluster to a high of 64.1% among those with all three disease clusters. Among those with two or more disease clusters, the rates varied from 28.3% for musculoskeletal and respiratory clusters to 41.8% for those with cardiometabolic and respiratory clusters. Individual with cardiometabolic conditions alone or in combination with other disease clusters were more likely to have polypharmacy. Compared to those with musculoskeletal and respiratory conditions, those with cardiometabolic and respiratory conditions had 1.68 times higher likelihood of polypharmacy. Conclusions. Rates of polypharmacy differed by specific disease clusters. Individuals with cardiometabolic condition were particularly at high risk of polypharmacy, suggesting greater surveillance for adverse drug interaction in this group.

成人慢性疾病群集与多重用药。
目标。该研究的主要目的是估计慢性疾病群中多重疾病个体的多重用药率,并检查其与多重用药的关系。方法。对10,528名年龄在21岁以上的个体进行横断面分析,这些个体在2009年医疗支出小组调查中至少有一种身体状况,包括心脏代谢(糖尿病或心脏病或高血压)、肌肉骨骼(关节炎或骨质疏松症)和呼吸(慢性阻塞性肺疾病(COPD)或哮喘)。采用卡方检验和logistic回归分析多种用药与多重发病之间的关系。结果。多药率从呼吸道聚集性患者的低7.2%到所有三种疾病聚集性患者的高64.1%不等。在患有两种或两种以上疾病集群的人群中,发病率从肌肉骨骼和呼吸集群的28.3%到心脏代谢和呼吸集群的41.8%不等。单独患有心脏代谢疾病或合并其他疾病群的个体更有可能出现多重用药。与患有肌肉骨骼和呼吸系统疾病的人相比,患有心脏代谢和呼吸系统疾病的人有1.68倍的多药可能性。结论。多种用药的比例因特定疾病群而异。患有心脏代谢疾病的个体尤其具有多重用药的高风险,这表明在这一组中需要对药物不良相互作用进行更多的监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书